The study aims to determine whether a nutritional supplement, FutureLife HIGH-ENERGY Smart food, given to caregivers/guardians to give to their HIV-positive infants and children for 6 months concurrently with antiretroviral therapy (ART) compared to standard of care results in improved growth and physical development as measured by an increase in height-for-age Z score (HAZ), weight-for-age Z score (WAZ) and mid-upper arm circumference (MUAC) at 6, 12 and 24 months. Secondary outcomes include determining whether a nutritional supplement has additional benefits over and above the benefits of ART in terms of improving bone turnover, improving the immune response (CD4 response and delaying the onset of AIDS), improving symptom management or tolerability of ART and finally improving ART adherence and promoting retention in care.
The following publications emanate from this project:
HE2RO staff involvedLawrence Long Matthew Fox Denise Evans Pertunia Manganye
Stay up to date
Receive newsletters and keep up to date with developments at HE2RO.